Paper Details

  1. Home
  2. Paper Details

The combination of atomoxetine and dronabinol for the treatment of obstructive sleep apnea: a dose-escalating, open-label trial.

Author: MessineoLudovico, NormanDaniel, OjileJoseph

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dronabinol, a cannabinoid, has a sedative effect and may be a potential treatment for obstructive sleep apnea (OSA). Atomoxetine, a noradrenergic reuptake inhibitor, has also shown promise in reducing OSA severity. This study investigated the combined effect of atomoxetine and dronabinol (Ato-Dro) in patients with OSA, finding that the combination was safe and may improve OSA severity.
Paper Details　
Original Abstract of the Article :
The potential sedative effect of dronabinol and the high expression of cannabinoid receptors on the hypoglossal motor nuclei makes this agent a good candidate for obstructive sleep apnea (OSA) pharmacotherapy to be tested with atomoxetine, a noradrenergic reuptake inhibitor that reduced OSA severity...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315604/

データ提供：米国国立医学図書館（NLM）

Atomoxetine and Dronabinol: A Novel Combination for Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by repeated pauses in breathing during sleep. This research investigates the potential of a novel combination therapy for OSA, using atomoxetine, a noradrenergic reuptake inhibitor, and dronabinol, a cannabinoid. The study explores the effects of this combination on OSA severity and examines its safety and tolerability.

Atomoxetine and Dronabinol: A Potential for Reducing OSA Severity

The study's findings suggest that the combination of atomoxetine and dronabinol might be effective in reducing OSA severity. The combination resulted in a significant reduction in the apnea-hypopnea index (AHI), a measure of OSA severity, compared to baseline.

OSA and Cannabinoids: A Promising Area of Research

This research highlights the potential of cannabinoids, like dronabinol, in managing OSA. The study's findings provide evidence for the combination of atomoxetine and dronabinol as a potential treatment strategy. Further research is needed to confirm its efficacy and safety in larger clinical trials.

Dr.Camel's Conclusion

This research explores the potential of a novel combination therapy for OSA, using atomoxetine and dronabinol. The study's findings suggest that this combination might be effective in reducing OSA severity. Further research is needed to confirm its efficacy and safety in larger clinical trials.

Date :
  1. Date Completed 2023-10-05
  2. Date Revised 2023-10-10
Further Info :

Pubmed ID

36805833

DOI: Digital Object Identifier

PMC10315604

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.